Ring substituents on substituted benzamide ligands indirectly mediate interactions with position 7.39 of transmembrane helix 7 of the D4 dopamine receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 2, 2012, Pages 472-485

  Ericksen, Spencer S ^a,e   Cummings, David F ^b,f   Teer, Michael E ^b   Amdani, Shahnawaz ^b   Schetz, John A ^b,c,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c Texas College of Medicine   (United States)

^d UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f Illinois State University and Carle BroMenn Medical Center Endowed Professor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(4 PYRIDIN 2 YLPIPERAZIN 1 YL)METHYL] 1H BENZIMIDAZOLE; 2 PHENYL 4 [4 (2 PYRIMIDINYL) 1 PIPERAZINYLMETHYL]IMIDAZOLE; 5 (N ISOBUTYL N METHYL)AMILORIDE; 5 FLUORO 2 [[4 (2 PYRIDINYL) 1 PIPERAZINYL]METHYL] 1H INDOLE; ABT 724; AMISULPRIDE; ARIPIPRAZOLE; BENZAMIDE DERIVATIVE; BROMOPRIDE; BUTACLAMOL; CLOZAPINE; CP 226269; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; EMONAPRIDE; ETICLOPRIDE; G PROTEIN COUPLED RECEPTOR; LOXAPINE; MEMBRANE PROTEIN; METCLOPRAMIDE; METHYLSPIPERONE; NAFADOTRIDE; OLANZAPINE; PLASMID DNA; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; SULPIRIDE; TIAPRIDE; TRANSMEMBRANE HELIX 7; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALANINE; ANIMALS; BENZAMIDES; BINDING SITES; CELL LINE, TRANSFORMED; DIETHYLAMINES; HEK293 CELLS; HUMANS; LIGANDS; MEMBRANE PROTEINS; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SALICYLAMIDES; SODIUM; STRUCTURE-ACTIVITY RELATIONSHIP; THREONINE;

EID: 84864121223     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.193979     Document Type: Article

References (39)

1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, and Roth BL (2009) Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 205:119-128.
2. Adham N, Tamm JA, Salon JA, Vaysse PJ, Weinshank RL, and Branchek TA (1994) A single point mutation increases the affinity of serotonin 5-HT1D α, 5-HT1D β, 5-HT1E and 5-HT1F receptors for β-adrenergic antagonists. Neuropharmacology 33:387-391.
3. Bello NT and Hajnal A (2010) Dopamine and binge eating behaviors. Pharmacol Biochem Behav 97:25-33.
4. Brioni JD, Moreland RB, Cowart M, Hsieh GC, Stewart AO, Hedlund P, Donnelly-Roberts DL, Nakane M, Lynch JJ 3rd, Kolasa T, et al. (2004) Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A 101:6758-6763. (Pubitemid 38586047)
5. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, et al. (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278-1287. (Pubitemid 41635416)
6. Charbit AR, Akerman S, and Goadsby PJ (2010) Dopamine: what's new in migraine? Curr Opin Neurol 23:275-281.
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318:1258-1265. (Pubitemid 350172884)
9. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V, et al. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330:1091-1095.
10. Cummings DF, Ericksen SS, Goetz A, and Schetz JA (2010) Transmembrane segment five serines of the D4 dopamine receptor uniquely influence the interactions of dopamine, norepinephrine, and Ro10-4548. J Pharmacol Exp Ther 333:682-695.
11. Cummings DF, Ericksen SS, and Schetz JA (2009) Three amino acids in the D2 dopamine receptor regulate selective ligand function and affinity. J Neurochem 110:45-57.
12. Depoortère R, Bardin L, Rodrigues M, Abrial E, Aliaga M, and Newman-Tancredi A (2009) Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors. Behav Pharmacol 20:303-311.
13. Ericksen SS, Cummings DF, Weinstein H, and Schetz JA (2009) Ligand selectivity of D2 dopamine receptors is modulated by changes in local dynamics produced by sodium binding. J Pharmacol Exp Ther 328:40-54.
14. Floresca CZ and Schetz JA (2004) Dopamine receptor microdomains involved in molecular recognition and the regulation of drug affinity and function. J Recept Signal Transduct Res 24:207-239. (Pubitemid 39332217)
15. Guan XM, Peroutka SJ, and Kobilka BK (1992) Identification of a single amino acid residue responsible for the binding of a class of β-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. Mol Pharmacol 41:695-698. (Pubitemid 23021458)
16. Hopkins AL, Mason JS, and Overington JP (2006) Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16:127-136. (Pubitemid 43221881)
17. Kortagere S, Gmeiner P, Weinstein H, and Schetz JA (2004) Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common receptor microdomain. Mol Pharmacol 66:1491-1499. (Pubitemid 39564775)
18. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627. (Pubitemid 29189265)
19. Lundstrom K, Turpin MP, Large C, Robertson G, Thomas P, and Lewell XQ (1998) Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. J Recept Signal Transduct Res 18:133-150. (Pubitemid 28299116)
20. Malmberg A, Jackson DM, Eriksson A, and Mohell N (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol 43:749-754. (Pubitemid 23146274)
21. Meltzer HY and Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177-197.
22. Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N, and Cussac D (2008) Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. Int J Neuropsychopharmacol 11:293-307. (Pubitemid 351482503)
23. Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, and Ashkenazi A (1992) A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360:161-163.
24. Parker EM, Grisel DA, Iben LG, and Shapiro RA (1993) A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine1B receptors. J Neurochem 60:380-383. (Pubitemid 23006745)
25. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, and Porsolt R (2001) The preclinical pharmacologic profile of tiapride. Eur Psychiatry 16 (Suppl 1):29s-34s.
26. Schetz JA, Chu A, and Sibley DR (1999) Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. J Pharmacol Exp Ther 289:956-964. (Pubitemid 29191254)
27. Schetz JA and Sibley DR (2000) Tandem sulfur-containing amino acids are epicritical determinants of dopamine D2 receptor pharmacology. Eur J Pharmacol 388:R5-R7. (Pubitemid 30077510)
28. Schetz JA and Sibley DR (2001) The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. J Pharmacol Exp Ther 296:359-363. (Pubitemid 32112461)
29. Seeman P (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4:56-73.
30. Simpson MM, Ballesteros JA, Chiappa V, Chen J, Suehiro M, Hartman DS, Godel T, Snyder LA, Sakmar TP, and Javitch JA (1999) Dopamine D4/D2 receptor selectivity is determined by a divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. Mol Pharmacol 56:1116-1126.
31. Stocchi F (2009) Dopamine receptor agonists in the treatment of advanced Parkinson's disease. Parkinsonism Relat Disord 15 (Suppl 4):S54-S57.
32. Suryanarayana S, Daunt DA, Von Zastrow M, and Kobilka BK (1991) A point mutation in the seventh hydrophobic domain of the α2 adrenergic receptor increases its affinity for a family of β receptor antagonists. J Biol Chem 266:15488-15492. (Pubitemid 21907674)
33. Suryanarayana S and Kobilka BK (1993) Amino acid substitutions at position 312 in the seventh hydrophobic segment of the β2-adrenergic receptor modify ligandbinding specificity. Mol Pharmacol 44:111-114. (Pubitemid 23230466)
34. Swift R (2010) Medications acting on the dopaminergic system in the treatment of alcoholic patients. Curr Pharm Des 16:2136-2140.
35. Tang L, Todd RD, Heller A, and O'Malley KL (1994) Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 268:495-502. (Pubitemid 24039127)
36. Wacker D, Fenalti G, Brown MA, Katritch V, Abagyan R, Cherezov V, and Stevens RC (2010) Conserved binding mode of human β2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc 132:11443-11445.
37. 1-adrenergic receptor. Nature 469:241-244.
38. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, and Schertler GF (2008) Structure of a β1-adrenergic G-protein-coupled receptor. Nature 454:486-491.
39. Woodward R, Daniell SJ, Strange PG, and Naylor LH (1994) Structural studies on D2 dopamine receptors: mutation of a histidine residue specifically affects the binding of a subgroup of substituted benzamide drugs. J Neurochem 62:1664-1669.